Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Gilead strikes again, penning $5bn deal to buy Tubulis

 April 7, 2026

Pharmaphorum

Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.

M&A / DealsRead full story

Post navigation

AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat Solidifies →
← 219: An Interview With Dr. Natalie Truba on the Psychological Aspects of Gene Therapy

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com